Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Lambers Heerspink HJ, de Zeeuw D.

Br J Clin Pharmacol. 2013 Oct;76(4):536-50. doi: 10.1111/bcp.12195. Review.

2.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
3.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
4.
5.

Antioxidants for chronic kidney disease.

Jun M.

Nephrology (Carlton). 2013 Aug;18(8):576-8. doi: 10.1111/nep.12103. Review. No abstract available.

PMID:
23865542
6.

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

Fernández Fernández B, Elewa U, Sánchez-Niño MD, Rojas-Rivera JE, Martin-Cleary C, Egido J, Ortiz A.

Minerva Med. 2012 Aug;103(4):219-34. Review.

PMID:
22805616
7.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.

Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4. Review.

8.
9.

Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.

Heerspink HJ.

Adv Chronic Kidney Dis. 2011 Jul;18(4):290-9. doi: 10.1053/j.ackd.2011.04.001. Review.

PMID:
21782135
10.

Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).

Formentini I, Bobadilla M, Haefliger C, Hartmann G, Loghman-Adham M, Mizrahi J, Pomposiello S, Prunotto M, Meier M.

Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii81-8. doi: 10.1093/ndt/gfs270. Epub 2012 Jun 25.

11.

Emerging drugs for chronic kidney disease.

Stefoni S, Cianciolo G, Baraldi O, Iorio M, Angelini ML.

Expert Opin Emerg Drugs. 2014 Jun;19(2):183-99. doi: 10.1517/14728214.2014.900044. Epub 2014 May 16. Review.

PMID:
24836744
12.

Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Kovesdy CP, Kalantar-Zadeh K.

Expert Opin Investig Drugs. 2008 Apr;17(4):451-67. doi: 10.1517/13543784.17.4.451 . Review.

PMID:
18363512
14.

Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease.

van Zuilen AD, Bots ML, Dulger A, van der Tweel I, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF.

Kidney Int. 2012 Sep;82(6):710-7. doi: 10.1038/ki.2012.137. Epub 2012 Jun 27.

PMID:
22739979
15.

Pharmacological strategies for kidney function preservation: are there differences by ethnicity?

Lakkis J, Weir MR.

Adv Ren Replace Ther. 2004 Jan;11(1):24-40. Review.

PMID:
14730536
16.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
17.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
18.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators.

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

19.

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.

Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF.

Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792. Epub 2011 Mar 3. Review.

20.

Educational paper: Progression in chronic kidney disease and prevention strategies.

Schaefer B, Wühl E.

Eur J Pediatr. 2012 Nov;171(11):1579-88. doi: 10.1007/s00431-012-1814-5. Epub 2012 Sep 12. Review.

PMID:
22968936
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk